



## OPEN ACCESS

## EDITED BY

Guihua Cui,  
Jilin Medical University, China

## REVIEWED BY

Muhammad Hanif,  
The University of Auckland, New Zealand  
Yang-Bao Miao,  
School of Medicine of University of Electronic  
Science and Technology of China, China

## \*CORRESPONDENCE

Guanqiao Jin,  
✉ jinguanqiao77@gxmu.edu.cn  
Litu Zhang,  
✉ zhanglitu@gmail.com  
Chen Wang,  
✉ wangchen88@gxmu.edu.cn

RECEIVED 14 June 2024

ACCEPTED 08 July 2024

PUBLISHED 19 July 2024

## CITATION

Wang H, Xia P, Kurboniyon MS, Fang S, Huang K,  
Ning S, Jin G, Zhang L and Wang C (2024), V-  
doped MoS<sub>2</sub> nanozymes providing reactive  
oxygen species and depleting glutathione for  
photothermally-enhanced  
nanocatalytic therapy.  
*Front. Pharmacol.* 15:1448867.  
doi: 10.3389/fphar.2024.1448867

## COPYRIGHT

© 2024 Wang, Xia, Kurboniyon, Fang, Huang,  
Ning, Jin, Zhang and Wang. This is an open-  
access article distributed under the terms of the  
[Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).  
The use, distribution or reproduction in other  
forums is permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original publication in this  
journal is cited, in accordance with accepted  
academic practice. No use, distribution or  
reproduction is permitted which does not  
comply with these terms.

# V-doped MoS<sub>2</sub> nanozymes providing reactive oxygen species and depleting glutathione for photothermally-enhanced nanocatalytic therapy

Haiyan Wang<sup>1</sup>, Penge Xia<sup>1</sup>, Mekhrdod S. Kurboniyon<sup>2</sup>,  
Shuhong Fang<sup>1</sup>, Kunying Huang<sup>1</sup>, Shufang Ning<sup>1</sup>, Guanqiao Jin<sup>1\*</sup>,  
Litu Zhang<sup>1\*</sup> and Chen Wang<sup>1\*</sup>

<sup>1</sup>Department of Research and Guangxi Cancer Molecular Medicine Engineering Research Center and Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer, Guangxi Medical University Cancer Hospital, Nanning, China, <sup>2</sup>National Academy of Sciences of Tajikistan, Dushanbe, Tajikistan

**Introduction:** The tumor microenvironment and multidrug resistance of tumor cells seriously impair the activity of the nanozymes.

**Methods:** Herein, a polyethylene glycol (PEG)-modified vanadium-doped molybdenum disulfide (V-MoS<sub>2</sub>@PEG) nanozymes were constructed to enhance anti-tumor activity through multi-enzymatic catalysis and photothermal effect with simultaneous reactive oxygen species replenishment and glutathione depletion.

**Results and discussion:** V-MoS<sub>2</sub>@PEG nanosheets exerted peroxidase activity by causing molybdenum ion (Mo<sup>4+</sup>) to react with hydrogen peroxide to form toxic hydroxyl radicals ( $\cdot$ OH). Meanwhile, the V-doping can deplete glutathione avoiding  $\cdot$ OH consumption. In addition, the high heat generated by V-MoS<sub>2</sub>@PEG nanozymes under near-infrared laser irradiation brought about a desirable local temperature gradient, which produced an enhanced catalytic effect by promoting band bending. Furthermore, the photothermally inspired polarized charge increased the permeability of the tumor cell membrane and promoted further aggregation of the nanozymes, which realized the combination of photothermal therapy with multi-enzymatic catalysis, solved the problem of multi-enzyme catalysis, and improved the anti-tumor efficiency.

## KEYWORDS

nanozymes, reactive oxygen species, glutathione, photothermal effect, tumor therapy

## 1 Introduction

With increasing global morbidity and mortality, cancer still poses a serious threat to human life and health. Since conventional treatment modalities (e.g., chemotherapy, radiotherapy, and surgical resection) have difficulty in achieving specific effects on malignant cells, these treatment modalities inevitably cause irreversible damage to normal cells and tissues in the body, resulting in poor patient prognosis. With the cross-vergence of nanomedicine and nanocatalysis, the utilization of nanozymes to

trigger enzyme-catalyzed reactions under the unique physiological characteristics of the tumor microenvironment to achieve catalytic therapy with substrate specificity and low toxic side effects has become a novel strategy for tumor treatment. However, due to the complexity of the tumor microenvironment, the catalytic activity of nanozymes is often compromised under physiological conditions to cause incomplete tumor growth inhibition, which motivates researchers to amplify the tumor inhibition effect by modulating the tumor microenvironment and developing multi-modal synergistic therapies. Tumor microenvironment (TME) refers to the microenvironment of tumor cells and their surroundings, which is closely related to the formation and metastasis of tumors (Li et al., 2018; Mishra et al., 2021; Sindhu et al., 2021). TME includes not only peripheral microvessels, fibroblasts, lymphocytes, immune cells, bone marrow-derived inflammatory cell signaling molecules, and other extracellular matrices but also a variety of biological features within tumor tissues, such as oxygen content, pH, and redox environment (Dong et al., 2021). The use of abnormal biochemical markers in the tumor tissue microenvironment and tumor cells is a potential target for exploring and developing new therapeutic modalities.

Reactive oxygen species (ROS) are a class of highly oxidative molecules that are by-products of aerobic metabolism and a specific cell signaling transcription factor. ROS in living organisms mainly includes superoxide radicals ( $\cdot\text{O}_2^-$ ), hydrogen peroxide ( $\text{H}_2\text{O}_2$ ), singlet oxygen ( $^1\text{O}_2$ ), and hydroxyl radicals ( $\cdot\text{OH}$ ), etc. (Asgharzadeh et al., 2017; Zhang et al., 2017; Sawant and Lilly, 2020; Wu et al., 2022). ROS is not only implicated in protein folding, cell proliferation, differentiation and migration, and signaling but also in respiration, defensive responses, and oxidative damage. In biological cells,  $\text{H}_2\text{O}_2$  is one of the most common ROS, mainly derived from the single-electron reduction of oxygen molecules, first to form  $\text{O}_2^-$ , and then catalyzed by superoxide dismutase to form  $\text{H}_2\text{O}_2$  (Willems et al., 2015; Ferreira et al., 2018; Yang et al., 2018; Zhang C. et al., 2020; Yang and Lian, 2020; Sahu et al., 2022; Zhang et al., 2022).  $\text{H}_2\text{O}_2$  has a broad range of catalytic activities and has been extensively used as a feedstock for activating drug release and generating intracellular oxygen. Tumor cells produce higher concentrations of  $\text{H}_2\text{O}_2$  compared to normal cells.  $\text{H}_2\text{O}_2$  can induce DNA damage and mutations, and increased  $\text{H}_2\text{O}_2$  concentrations also activate hypoxia-inducible factor-1 (Masoud and Li, 2015; Ma et al., 2022). Activated HIF-1 plays an essential role in apoptosis, invasion, metastasis, and angiogenesis (Albadari et al., 2019; Infantino et al., 2021).  $\text{H}_2\text{O}_2$  is highly biotoxic because it can be converted into various reactive free radicals, which can disrupt the redox metabolic balance in cells, especially by interacting with transition metal ions to generate highly reactive  $\cdot\text{OH}$ .

In addition, the regulation of the nanozymes can also affect their temperature to increase the catalytic activity of the nano-enzymes, leading to better and more effective tumor catalysis. Photothermal therapy (PTT), which collaboratively enhances the catalytic activity and therapeutic efficacy of nanozymes through the photothermal effect, is regarded as a promising therapeutic strategy (Wang et al., 2019; Zhang Q. et al., 2020; Yang et al., 2020; Zhou et al., 2020). For example, Fan and colleagues developed yolk-shell gold@carbon nanozymes, in which a synergistic effect of photothermal enhancement of enzyme-like activity was observed, exhibiting efficient tumor-destroying capabilities (Fan et al., 2018). Additionally, a  $\text{MnO}_2@\text{HMCu}_{2-x}\text{S}$  nanocomposite with photothermally enhanced glutathione (GSH) depletion was constructed

to induce ferrite deposition for efficient tumor ablation (An et al., 2019). Nanozymes exhibit enhanced GSH depletion and ROS generation under photothermal conditions, leading to more efficient tumor therapeutic effects (Cao et al., 2019; Kobayashi and Choyke, 2019; Ma et al., 2019; Dong et al., 2020; An et al., 2021; Li et al., 2021; Li et al., 2023). Therefore, combining photothermal properties and photothermal therapy based on the material itself could further enhance the catalytic activity of the nanozymes, thus promoting the synergistic effect of PTT and tumor nanocatalytic therapy (Cui et al., 2013; Cui et al., 2017; Murugan et al., 2019; Yadav et al., 2019; Wang et al., 2021; Sethulekshmi et al., 2022; Feng et al., 2023; Ma et al., 2023).

Herein, we designed a photothermally enhanced m-polyethylene glycol-amine (mPEG-NH<sub>2</sub>)-modified vanadium-doped molybdenum disulfide nanosheets (V-MoS<sub>2</sub>@PEG) as a biocatalytic therapeutic platform. The hydrophilic modification of V-MoS<sub>2</sub> by PEG enhances the biocompatibility of V-MoS<sub>2</sub>@PEG, which can be phagocytosed by the cells. After the entry of V-MoS<sub>2</sub>@PEG into TME, due to the specific acidic conditions, V-MoS<sub>2</sub>@PEG undergoes hydrolysis, and molybdenum ions ( $\text{Mo}^{4+}$ ) and vanadium ions ( $\text{V}^{4+}$ ) are released, which interact with  $\text{H}_2\text{O}_2$  in TME to generate toxic  $\cdot\text{OH}$ , at the same time, due to the valorization of Mo ions and V ions, GSH in TME can be consumed, which results in the V-MoS<sub>2</sub>@PEG displaying multi-enzyme activity. Meanwhile, V-MoS<sub>2</sub>@PEG nanozymes exhibit a strong photothermal effect, and under 808 nm laser irradiation, a controlled temperature gradient can be generated in the local area, which warms up to 55°C within 5 min, and the multi-enzymatic activity is also dramatically increased, realizing photothermal-enhanced multi-enzymatic therapeutic effect.

## 2 Experimental section

### 2.1 Materials

Ammonium molybdate tetrahydrate ( $(\text{NH}_4)_6\text{Mo}_7\text{O}_{24}\cdot 4\text{H}_2\text{O}$ , 98%), thioacetamide ( $\text{C}_2\text{H}_5\text{NS}$ , 98%), ammonium vanadate ( $\text{NH}_4\text{VO}_3$ , 95%),  $\text{H}_2\text{O}_2$ , dextrose monohydrate ( $\text{C}_6\text{H}_{12}\text{O}_6\cdot\text{H}_2\text{O}$ , 98%), mPEG-NH<sub>2</sub> (average molecular weight is 3,400), 3,3',5,5'-tetramethylbenzidine (TMB), GSH, dimethyl sulfoxide (DMSO), and 5,5'-dithiobis(2-nitrobenzoic acid) (DNTB) were purchased from Sigma-Aldrich. RPMI 1640 medium, Methylthiazolyl tetrazolium (MTT, > 98%), fluorescein isothiocyanate (FITC, 95%), 2',7'-dichlorofluorescein diacetate (DCFH-DA), Mouse Urea ELISA Kit, Mouse Crea (Cr) ELISA Kit, Mouse Alanine Aminotransferase (ALT) ELISA Kit, Mouse Aspartate Aminotransferase (AST) ELISA Kit, 4',6-diamidino-2-phenylindole (DAPI), calcineurin-AM ( $\geq 97\%$ ), propidium iodide (PI,  $\geq 99\%$ ), JC-1 staining kit, H&E staining, and annexin V-FITC/PI apoptosis detection kit purchased from Beyotime Biotechnology. Phosphate buffered saline (PBS) and Dulbecco's Modified Eagle's Medium (DMEM) were purchased from Gibco Life Technologies. All chemical reagents in this paper were not further purified.

### 2.2 Characterization

Transmission electron microscope (TEM) images showing morphology were taken with a FEI Tecnai T20 under 200 kV

acceleration voltage. The crystal structure of materials was measured by X-ray diffractometer (XRD, RigakuD/MAX-TTR-III) equipped with Cu K $\alpha$  radiation ( $\lambda = 0.154$  nm) at 40 kV and 40 mA. The samples' ultraviolet and visible spectrophotometric (UV-vis) absorbance spectra were acquired with a UV-1601 spectrophotometer. X-ray photoelectron spectroscopy (XPS, ESCALAB 250Xi) was applied to measure the X-ray photoelectron spectra. The surface groups were measured by Fourier Transform infrared spectrometer (FT-IR, Perkin-Elmer 580B). The generation of ROS was detected by electron spin resonance spectroscopy (ESR, Bruker D-76287). The flow cytometry assays were conducted on a BD Accuri C6 flow cytometer (United States). A confocal laser scanning microscope (CLSM, Leica TCS SP8) obtained the fluorescence image.

### 2.3 Synthesis of V-MoS<sub>2</sub>@PEG

(NH<sub>4</sub>)<sub>6</sub>Mo<sub>7</sub>O<sub>24</sub>·4H<sub>2</sub>O (1.1455 g) and C<sub>2</sub>H<sub>5</sub>NS (1.9722 g) were weighed in a 1:4 molar ratio, then a quantity of C<sub>6</sub>H<sub>12</sub>O<sub>6</sub>·H<sub>2</sub>O (0.0012 g) and NH<sub>4</sub>VO<sub>3</sub> (0.1616 g) were added an appropriate amount of deionized water (60 mL), and stirred for 1 h until completely dissolved, after that the solution was transferred to a 100 mL polytetrafluoroethylene (PTFE) lined reactor and dried in a blast oven at 200°C for 24 h. The final product was washed three times with anhydrous ethanol and deionized water, and dried for 8 h in an oven at 60°C.

Then, 50 mg of V-MoS<sub>2</sub> product was weighed in 30 mL of deionized water and 25 mg of the mPEG-NH<sub>2</sub> in 20 mL of deionized water. Slowly drop the dissolved mPEG-NH<sub>2</sub> into the deionized water, where the V-MoS<sub>2</sub> product was dissolved and stirred at room temperature for 12 h. The product was centrifugated and dried in an oven at 60°C for 6 h to obtain the final V-MoS<sub>2</sub>@PEG nanozymes.

### 2.4 ROS generation estimation

To evaluate the enzymatic-like kinetics, V-MoS<sub>2</sub>@PEG (50  $\mu\text{g mL}^{-1}$ , 100  $\mu\text{g mL}^{-1}$ , 150  $\mu\text{g mL}^{-1}$ , 200  $\mu\text{g mL}^{-1}$ , and 250  $\mu\text{g mL}^{-1}$ ), TMB (10 mM), and H<sub>2</sub>O<sub>2</sub> concentrations (final concentrations of 50 mM) were added to 2 mL of PBS solution at 25°C room temperature. The absorbance of the same material concentration was then measured after different reaction times.

### 2.5 GSH depletion estimation

V-MoS<sub>2</sub>@PEG (100  $\mu\text{g mL}^{-1}$ , 150  $\mu\text{g mL}^{-1}$ , 200  $\mu\text{g mL}^{-1}$ , and 250  $\mu\text{g mL}^{-1}$ ) was mixed with GSH (5 mM) and H<sub>2</sub>O<sub>2</sub> (5 mM) in PBS solution. Followed by adding DMSO at 0, 2, 4, 6, 8, and 10 min to detect-SH of GSH. The changes in absorbance at 412 nm were recorded via a UV-vis spectrophotometer.

### 2.6 Photothermal effect estimation

Different concentrations of materials (25  $\mu\text{g mL}^{-1}$ , 50  $\mu\text{g mL}^{-1}$ , 100  $\mu\text{g mL}^{-1}$ , and 200  $\mu\text{g mL}^{-1}$ ) were irradiated with an

808 nm laser of 0.6 W cm<sup>-2</sup> power, and thermographic pictures were taken. The same concentration of V-MoS<sub>2</sub>@PEG solution was irradiated by 808 nm laser with different power (0.4 W cm<sup>-2</sup>, 0.6 W cm<sup>-2</sup>, 0.8 W cm<sup>-2</sup>, and 1.0 W cm<sup>-2</sup>) for 300 s at room temperature and using an infrared thermal camera (FLIR System E40) to photograph. Pure water, as the control group, was irradiated in the same way. Irradiated V-MoS<sub>2</sub>@PEG at 0.6 W cm<sup>-2</sup> for four cycles, each composed of 300 s heating and natural cooling periods, to further test the photothermal stability.

### 2.7 In vitro anti-tumor estimation

The 4T1 (mouse breast cancer cells) and L929 (mouse fibroblast cells) cells were purchased from the Cell Bank. Culturing Cells in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C and 5% CO<sub>2</sub> humidity. The 4T1 cells were inoculated into petri dishes and cultured for 24 h, and then the medium was replaced with fresh medium containing V-MoS<sub>2</sub>@PEG (100  $\mu\text{g mL}^{-1}$ ) and incubated for 0.5, 1, and 3 h, respectively. Rinsed the treated 4T1 cells twice with PBS for observation of CLSM.


Seeding the 4T1 cells into 96-well plates and culturing for 24 h. The cell culture was then renewed with a fresh medium containing different concentrations of V-MoS<sub>2</sub>@PEG. The light-related groups were irradiated with an 808 nm laser (0.4 W cm<sup>-2</sup>). 4T1 cells were handled under conditions: 1. Control; 2. NIR (808 nm, 0.4 W cm<sup>-2</sup>, 10 min); 3. V-MoS<sub>2</sub>@PEG (100  $\mu\text{g mL}^{-1}$ ); 4. V-MoS<sub>2</sub>@PEG (100  $\mu\text{g mL}^{-1}$ ) + NIR (10 min). After 4 h of co-incubation at 37°C, the NIR correlation group was subjected to 808 nm laser irradiation, followed by adding DCFH-DA (10  $\mu\text{M}$ ) and incubating in the dark for a further 40 min. After different treatments, the cells were rinsed twice with PBS for CLSM observation.

Seeding the 4T1 cells into 96-well plates and culturing for 24 h. The 4T1 cells were handled under conditions: 1. Control; 2. NIR (808 nm, 0.4 W cm<sup>-2</sup>, 10 min); 3. V-MoS<sub>2</sub>@PEG (100  $\mu\text{g mL}^{-1}$ ); 4. V-MoS<sub>2</sub>@PEG (100  $\mu\text{g mL}^{-1}$ ) + NIR (10 min). After 4 h of co-incubation at 37°C, the NIR correlation group was subjected to 808 nm laser irradiation, followed by a co-incubation with calcein-AM and PI for 30 min. Finally, 4T1 cells were washed repeatedly with PBS and imaged using CLSM.

Seeding the 4T1 cells into 96-well plates and culturing for 24 h 4T1 cells were handled under conditions: 1. Control; 2. NIR (808 nm, 0.4 W cm<sup>-2</sup>, 1 min); 3. V-MoS<sub>2</sub>@PEG (100  $\mu\text{g mL}^{-1}$ ); 4. V-MoS<sub>2</sub>@PEG (100  $\mu\text{g mL}^{-1}$ ) + NIR (1 min). Using Annexin V-FITC Apoptosis Detection Kit to double stain the 4T1 cells flow cytometric analysis. 4T1 cells were inoculated into petri dishes and cultured for 24 h. Then, 4T1 cells were treated with the following conditions: 1. Control; 2. NIR (808 nm, 0.4 W cm<sup>-2</sup>, 10 min); 3. V-MoS<sub>2</sub>@PEG (100  $\mu\text{g mL}^{-1}$ ); 4. V-MoS<sub>2</sub>@PEG (100  $\mu\text{g mL}^{-1}$ ) + NIR (10 min). JC-1 staining of 4T1 cells was performed using the above process.

### 2.8 In vivo anti-tumor estimation

4-week-old female BALB/c mice were bought from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China)



(1100111084356). The animal study protocol was approved by the Ethics Committee of Guangxi Medical University Cancer Hospital (protocol code KY 2022-129/130 and approved on 25 February 2022) for studies involving animals. The 4T1 breast cancer orthotopic model was established by subcutaneously injecting  $1 \times 10^6$  4T1 cancer cells (100  $\mu$ L) into the breast of the mouse. When tumor sizes are about  $\sim 70$  mm<sup>3</sup>, the tumor-bearing BALB/c mice were randomly allocated into four groups and injected with intravenous injections ( $n = 4$ ): 1. Control; 2. NIR (808 nm, 0.4 W cm<sup>-2</sup>, 10 min); 3. V-MoS<sub>2</sub>@PEG (10 mg kg<sup>-1</sup>); 4. V-MoS<sub>2</sub>@PEG (10 mg kg<sup>-1</sup>) + NIR (10 min) at 0, 3, 6, and 9 d. On day 14, the 808 nm laser irradiation operations were executed. We weighed the mice and the size of the tumors every day. Tumor volume = length  $\times$  width<sup>2</sup>/2 is the formula for calculating tumor volume. Mice were treated for a fortnight, and at the end of the treatment, mice were executed, and tumors were collected. The

tumor inhibition rate of each group was calculated according to the formula of tumor inhibition rate of each group: tumor inhibition rate =  $(V_{\text{control}} - V_{\text{experiment}})/V_{\text{control}} \times 100\%$ . Finally, sections of tumors and major organs (heart, liver, spleen, lung, and kidney) were collected from each group for H&E staining and Ki67 assay.

## 2.9 Statistical analysis

All experimental data were used directly for statistical analyses and are expressed as mean  $\pm$  S. D. The multiple comparisons among various groups were tested by the one-way analysis variance (ANOVA) with Bonferroni's post-hoc test in the Origin 2021 software. The probability ( $p$ ) value was presented by different numbers of asterisks (\*) according to its actual value (\* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ).



## 3 Result and discussion

### 3.1 Synthesis and characterization of V-MoS<sub>2</sub>@PEG

V-MoS<sub>2</sub> nanoflowers (NFs) were synthesized through a two-step hydrothermal process. The MoS<sub>2</sub> and the V-MoS<sub>2</sub> were characterized and analyzed, and TEM images were taken for MoS<sub>2</sub> and V-MoS<sub>2</sub> NFs, respectively. Figures 1A, B demonstrate the nanoflowers structures formed by aggregates and single clusters of nanoflakes of MoS<sub>2</sub> within the field of view, respectively, with individual MoS<sub>2</sub> nanoflowers of about 50 nm and uniformly regular in size, with the edges taking on the shape of nanoflowers petals. Compared to the simple MoS<sub>2</sub> NFs, the V-MoS<sub>2</sub> NFs exhibit an irregular shape, while the nanoflowers become larger. As shown in Figure 1C, the V-MoS<sub>2</sub> NFs could not be divided into accurate boundaries, while the shape of the nanoflowers surrounded by the lamellae became loose, and the individual V-MoS<sub>2</sub> NFs still retained the nanosheet structure, which is a cluster stacked by a piece of nanosheets. As seen in Figures 1D, E, the number of the lamellae and the thickness of the lamellae are not uniform, and the lamellae size is about 150 nm approximately. These are also confirmed in the high-resolution TEM images (Figure 1F), where the lamellar structure of V-MoS<sub>2</sub> NFs can be seen, with some “petals” consisting of five nanosheets and others consisting of only 2–3 nanosheets and the presence of lattice fringes is also observed, proving the existence of a lattice structure of V-MoS<sub>2</sub>. The ultra-small and uniform morphology create favorable conditions for the subsequent experiments. The elemental map of V-MoS<sub>2</sub> NFs (Figure 1G) shows the homogeneous distributions of Mo, S, and V in V-MoS<sub>2</sub> NFs, indicating the V element was successfully doped to synthesized V-MoS<sub>2</sub> NFs.

In addition, the structure of V-MoS<sub>2</sub> was determined by the XRD analysis (Figure 1H). The XRD patterns of MoS<sub>2</sub> and V-MoS<sub>2</sub> match well with the MoS<sub>2</sub> monoclinic phase (JCPDS No. 87-2416). From the obtained XRD spectra, it is shown that the (002), (100), and (110) planes of MoS<sub>2</sub> and V-MoS<sub>2</sub> NFs are broad and pronounced, suggesting the predominance of monolayer and few-layer flower-like patterns with excellent crystallinity. After doping V ions, the characteristic V-MoS<sub>2</sub> peaks showed slight shifts at 16.25°, 32.8°, and 58.4°. This may be due to the doping of the V element. The V atoms enter into the crystal structure of MoS<sub>2</sub>, which causes the change of the symmetry of the crystal cell and shifts the crystal faces.


The chemical composition of the V-MoS<sub>2</sub> NFs was determined via energy-dispersive X-ray spectroscopy (EDS). The coexistence of Mo, S, and V signals was confirmed via the EDS analysis (Figure 1I). Hence, it can be inferred that the synthesis of V-MoS<sub>2</sub> NFs was successful. Through the analysis of each elemental component in Figure 1J, it can be concluded that the Mo element accounts for 46.28%, the V element accounts for 3.72%, and the S element accounts for 50.00%, and the V doping process may be replacing some of the Mo atoms in MoS<sub>2</sub>. Furthermore, the near-surface chemistry of a catalyst affects its catalytic activity. XPS was used to analyze the composition of V-MoS<sub>2</sub> NFs. An XPS survey spectrum showed that V-MoS<sub>2</sub>@PEG comprised V, C, Mo, S, and O (Figure 1K). The high-resolution XPS spectrum of Mo 3d exhibited two spin-orbit splitting, Mo 3d<sub>5/2</sub> and Mo 3d<sub>3/2</sub>. It is shown in Figure 1L that the two highest peaks can be divided into

two groups of four peaks each, indicating that V-MoS<sub>2</sub> is rich in Mo<sup>2+</sup>. A pair of double peaks at the lower binding energy of 229.2 eV and 232.3 eV appears for Mo 3d<sub>5/2</sub> and Mo 3d<sub>3/2</sub> of 1T-MoS<sub>2</sub>, respectively. The other double high binding energy peaks belong to Mo 3d<sub>5/2</sub> and Mo 3d<sub>3/2</sub> of 2H-MoS<sub>2</sub>, respectively, suggesting that V-MoS<sub>2</sub> consists of 1T and 2H phases. In particular, two small peaks were fitted at 235.1 eV and 225.7 eV, respectively. Hydrothermal synthesis may cause the oxidation of elemental Mo, with MoO<sub>2</sub> (Mo<sup>4+</sup>), which can be seen as the affiliated peak at 235.1 eV. The slight oxidation of elemental Mo during the synthesis process changes its metallic nature to give it a lower resistivity, which may favor the occurrence of redox reactions, as this reduction in resistivity may facilitate the charge transfer of the catalyst. It can be seen that the peak intensity of V is lower, which is due to the higher density of MoS<sub>2</sub> and lower doping of V, and the generated VS<sub>2</sub> will be partially shielded by the shielding effect. In addition, the presence of metal sulfides (S<sup>2-</sup>) was analyzed by fitting the peaks to S 2p, with the two peaks for S 2p<sub>1/2</sub> and S 2p<sub>3/2</sub> located at 161.3 eV and 162.5 eV, respectively (Figure 1M). In the high-resolution XPS spectrum of V (Figure 1N), two peaks at 512.8 eV and 520.6 eV can be seen belonging to the V<sup>2+</sup> ions of V 2p<sub>3/2</sub> and V 2p<sub>1/2</sub>, respectively. Two other peaks, V 2p<sub>3/2</sub> and V 2p<sub>1/2</sub>, corresponding to the V<sup>4+</sup> ion, are located at 516.6 eV and 524.0 eV. XPS results show that the metal of V-MoS<sub>2</sub> exists in various valence states and is relatively stable, favoring subsequent redox reactions.

Subsequently, the as-prepared V-MoS<sub>2</sub> NFs were functionalized with PEG, which yielded V-MoS<sub>2</sub>@PEG NFs with excellent biocompatibility and physiological stability. Determination of the surface charge of V-MoS<sub>2</sub> NFs used zeta potential measurements. As illustrated in Figure 1O, V-MoS<sub>2</sub> NFs have tested the strength of mutual repulsion or attraction, and it can be seen that V-MoS<sub>2</sub> NFs clearly show a negative potential of -44.5 mV, so the surface modification of V-MoS<sub>2</sub> NFs was carried out by the addition of positively charged mPEG-NH<sub>2</sub> on top of the negatively charged V-MoS<sub>2</sub>. The potential of V-MoS<sub>2</sub>@PEG was significantly lower after modification, showing a negative potential of -13.5 mV. Additionally, tests using FT-IR spectroscopy before and after modification were performed to analyze whether PEG could be successfully modified on the V-MoS<sub>2</sub> NFs surface. As shown in Figure 1P, the unmodified V-MoS<sub>2</sub> NFs surface has characteristic absorption peaks at 1,637 cm<sup>-1</sup> and 1,385 cm<sup>-1</sup> due to the uncleaned carboxyl groups left on the surface during the preparation process. The modified V-MoS<sub>2</sub> NFs have prominent characteristic absorption peaks (3,365 cm<sup>-1</sup>, 2,916 cm<sup>-1</sup>, 2,850 cm<sup>-1</sup>, 1,636 cm<sup>-1</sup>, and 3,365 cm<sup>-1</sup>) of NH<sub>2</sub>, -CH<sub>3</sub>, -CH<sub>2</sub>, and C-O-C groups associated with mPEG-NH<sub>2</sub>, indicating that mPEG-NH<sub>2</sub> was successfully modified onto the surface of V-MoS<sub>2</sub> NFs. As a result, the negatively charged V-MoS<sub>2</sub> NFs were deposited on the positively charged mPEG-NH<sub>2</sub> by decisive electrostatic action to obtain the final V-MoS<sub>2</sub>@PEG composites.

### 3.2 *In vitro* catalytic activity of V-MoS<sub>2</sub>@PEG

The abundant Mo<sup>2+</sup> and the photothermal triggering property produced a large amount of ·OH, which was



**FIGURE 2**  
 ROS production capacity of V-MoS<sub>2</sub> NFs. **(A)** Oxidation of TMB to produce ·OH in different pH environments (V-MoS<sub>2</sub> 200 µg mL<sup>-1</sup>). **(B)** Material concentration-dependent oxidation of TMB indicates ·OH generation under different conditions. **(C)** Time-dependent oxidation of TMB indicates ·OH generation under different conditions. **(D)** Color response of TMB after being oxidized, (1) and (6) are controls, (2)–(5) correspond to the color response of TMB after 5 min of reaction with 50, 100, 150, and 200 µg mL<sup>-1</sup>, respectively, and (7)–(10) correspond to the picture after 2–5 min of reaction with 200 µg mL<sup>-1</sup>, respectively. **(E–H)** Absorbance spectra of glutathione depletion over 0–10 min of different substance concentrations (GSH 5 mg mL<sup>-1</sup>). **(I)** ESR spectra for V-MoS<sub>2</sub> NFs and MoS<sub>2</sub> NFs in the presence of DMPO and H<sub>2</sub>O<sub>2</sub> (V-MoS<sub>2</sub> 200 µg mL<sup>-1</sup>; MoS<sub>2</sub> 200 µg mL<sup>-1</sup>; H<sub>2</sub>O<sub>2</sub> 0.5 mM).

confirmed in subsequent experiments. After mixing V-MoS<sub>2</sub>@PEG with H<sub>2</sub>O<sub>2</sub> solution, the production of ·OH was detected by varying the solution acid-base values (pH = 5.4, 6.5, and 7.4) (Figure 2A). The ·OH production could be detected at pH = 5.4, whereas slight ·OH production signals were detected at pH 6.5 and 7.4, suggesting that V-MoS<sub>2</sub> has better pH responsiveness and can hydrolyze ·OH using H<sub>2</sub>O<sub>2</sub> from TME in the acidic environment of TME. The solution pH was controlled to 5.4, and the H<sub>2</sub>O<sub>2</sub> concentration was unchanged. The H<sub>2</sub>O<sub>2</sub> decomposed into ·OH (Figure 2B) in a material-concentration (50, 100, 150, 200, and 250 µg mL<sup>-1</sup>)-dependent manner, controlling the material concentration is constant (150 µg mL<sup>-1</sup>) H<sub>2</sub>O<sub>2</sub> decomposes to ·OH in a time-dependent manner, and these can be detected by the TMB substrate (Figure 2C). As the concentration of the material increases, more ·OH is generated, while the generated ·OH can effectively accumulate over time. Figure 2D shows photographs of TMB color development at different material concentrations and times for the same concentration,

respectively. The change in the color of TMB becomes darker and darker with the concentration of the material and the time it is left in place, which is consistent with the results of the UV test of TMB. As shown in Figures 2E–H, to verify the effective depletion of glutathione by V-MoS<sub>2</sub>, 5 mg mL<sup>-1</sup> of GSH was added using different material concentrations (100, 150, 200, and 250 µg mL<sup>-1</sup>), and the glutathione absorbance at different times was detected after different times of reaction. A concentration-dependent and time-dependent trend in glutathione depletion can be found; the decrease in UV absorption peaks indicated the degradation of GSH, suggesting that V-MoS<sub>2</sub> could circulate in TME with sufficient GSH and H<sub>2</sub>O<sub>2</sub> and generate ·OH to kill tumor cells. In addition, an ESR assay using DMPO was performed to detect the production of ·OH under different conditions. As shown in Figure 2I, MoS<sub>2</sub> and V-MoS<sub>2</sub> solutions were mixed in H<sub>2</sub>O<sub>2</sub>, respectively, and a clear signal could be observed, whereas there was no signal strength was detected in the control group, which proved that V-MoS<sub>2</sub> has a more desirable ·OH generation ability compared to MoS<sub>2</sub>,




FIGURE 3

Inspection of photothermal performance of V-MoS<sub>2</sub>@PEG NFs. (A) Warming curves of different concentrations of materials under 808 nm NIR irradiation within 5 min. (B) Infrared thermograms of different concentrations of materials under 808 nm NIR irradiation (0–3.5 min, photographed at 30 s intervals). (C) Warming curves of materials under 808 nm NIR irradiation at different power intensities within 5 min (V-MoS<sub>2</sub>@PEG 100 µg mL<sup>-1</sup>). (D) Infrared thermograms of the materials under 808 nm NIR light irradiation at different power intensities (0–3.5 min, photographed at 30 s intervals). (E) Photothermal stability of V-MoS<sub>2</sub>@PEG NFs under 808 nm laser (0.8 W cm<sup>-2</sup>) for 5 min and cooling. (F) Photothermal stability of 100 µg mL<sup>-1</sup> V-MoS<sub>2</sub>@PEG NFs and 0.6 W cm<sup>-2</sup> under 808 nm laser irradiation for four on/off cycles.

Further evidence that the doping of element V enhances the generation of ·OH.


### 3.3 Characterization of the photothermal performance of V-MoS<sub>2</sub>@PEG

Inspired by these excellent properties of V-MoS<sub>2</sub>@PEG NFs, *in vitro* photothermal-enhanced nanocatalytic therapeutic efficacy was evaluated with 808 nm near-infrared (NIR) light. The photothermal effect of V-MoS<sub>2</sub>@PEG NFs was investigated by irradiating different concentrations of V-MoS<sub>2</sub>@PEG NFs solution using an 808 nm laser. In Figure 3A, the temperature change curves of the V-MoS<sub>2</sub>@PEG NFs with different concentrations were measured during the 5 min heating process, and it can be seen that compared with the temperature change curves of pure water, V-MoS<sub>2</sub>@PEG NFs have better photothermal effect, and the temperature change curves become more and more obvious as the concentration continues to rise, while the temperature of pure water changed slightly. In Figure 3B, this temperature change is reflected by a thermal infrared map. Different concentrations of the V-MoS<sub>2</sub>@PEG were set up and given 808 nm laser irradiation for 3.5 min respectively, and photographs of the infrared thermograms were taken at intervals of 30 s, and a clear temperature change of the V-MoS<sub>2</sub>@PEG NFs could be observed. In Figure 3C, the concentration of V-MoS<sub>2</sub>@PEG NFs was set to 100 µg mL<sup>-1</sup> and measured the temperature rise curve over time at different powers of the 808 nm laser (0.4 W cm<sup>-2</sup>,

0.6 W cm<sup>-2</sup>, 0.8 W cm<sup>-2</sup>, and 1.0 W cm<sup>-2</sup>). With the increase of power, the temperature rise rate of V-MoS<sub>2</sub>@PEG significantly increases, with power and concentration-dependent photothermal properties. In Figure 3D, these photothermal changes were reflected in an infrared thermal image; it can be observed that as the 808 nm laser power increases, the temperature change of V-MoS<sub>2</sub>@PEG becomes more and more obvious, with a good photothermal effect. In addition, with the 0.8 W cm<sup>-2</sup> 808 nm laser irradiating, the curve can be fitted according to the heating-cooling curve, and the heat transfer time constant of the system is obtained as 226.9 s. V-MoS<sub>2</sub>@PEG NFs have a great photothermal conversion efficiency as 31.1% (Figure 3E). The great photostability of V-MoS<sub>2</sub>@PEG NFs was also verified by three laser power on/off cycles, in which the photothermal effect showed only a slight change (Figure 3F), which indicated that V-MoS<sub>2</sub>@PEG has excellent photothermal stability.

### 3.4 *In vitro* cytotoxicity of V-MoS<sub>2</sub>@PEG

To evaluate the cellular internalization performance of V-MoS<sub>2</sub>@PEG NFs, we labeled it with FITC and denoted it as FITC-labeled V-MoS<sub>2</sub>@PEG NFs. At different time points, the *in vitro* cellular take-up of FITC-labelled V-MoS<sub>2</sub>@PEG by 4T1 cells was evaluated using CLSM. As given in Figure 4A, the fluorescence signals of FITC became stronger with a prolonged incubation time, exhibiting that the V-MoS<sub>2</sub>@PEG exhibited great cellular uptake efficiency. As mentioned above,



**FIGURE 4** Inspection of photothermal performance. (A) CLSM images and corresponding line-scan profiles of 4T1 cells incubated with V-MoS<sub>2</sub>@PEG NFs (100 µg mL<sup>-1</sup>) at different time intervals. (B) Viability of L929 cells and 4T1 cells cultured with different concentrations of V-MoS<sub>2</sub>@PEG (the cell viability of 4T1 cells cultured with different concentrations and given 808 nm NIR light stimulation of V-MoS<sub>2</sub>@PEG). (C) Calcein-AM/PI double staining: 1) control, 2) 808 nm laser, 3) V-MoS<sub>2</sub>@PEG, 4) V-MoS<sub>2</sub>@PEG + 808 nm laser. (D) CLSM images and (D) the fluorescence quantification of 4T1 cells stained with DCFH-DA after different treatments. (E) Fluorescein-annexin V and PI staining assay, and (F) the corresponding quantitative analysis of 4T1 cells handled with different formulations. The data are presented as mean ± standard deviation (S.D.) (n = 3) with \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.

tumor cells are more susceptible to electrical charges than normal cells, thus allowing more drugs to enter the tumor cells, enabling passive targeting functions and accumulation of more drugs at the tumor site. The biocompatibility and therapeutic efficacy of normal cells and tumor cells were evaluated using an MTT assay

(Figure 4B). Repeated the experiment three times (n = 3). There were no significant changes in L929 cell survival compared to the control when we only gave the NIR irradiation or different concentrations of V-MoS<sub>2</sub>@PEG NFs. However, the 4T1 cells were handled with different treatments. At the V-MoS<sub>2</sub> and the






FIGURE 5

*In vivo* treatment of mice with 4T1 tumors. (A) Schematic representation of the establishment of the 4T1 tumor model. (B) Mouse weights and (C) tumor volumes in different groups during the 14-day treatment. (D) Tumors weights in various groups: 1) control, 2) NIR, 3) V-MoS<sub>2</sub>@PEG, 4) V-MoS<sub>2</sub>@PEG + NIR ( $n = 4$  biologically independent mice, \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , ns indicating no significant differences) (E) Tissue section images of heart, liver, spleen, lung, and kidney in different groups. (F) H&E of tumors after different treatments and Ki67 staining assay. (G–J) Detection of liver and kidney functions in different treatment groups.

V-MoS<sub>2</sub>@PEG + NIR groups, concentration-dependent cytotoxicity was exhibited in 4T1 cells with a significant reduction in cytotoxicity, indicating that V-MoS<sub>2</sub>@PEG had a photothermally-enhanced effect of promoting cells death, which

due to the collaborative effect of nano-enzymes and pyroelectric catalysis. After treatments with different experimental groups, the cells were co-stained with calcein-AM and PI to visually distinguish the living cells from dead cells. As shown in Figure 4C

the control groups and 808 nm laser irradiation group had almost no cell damage, while a majority of the dead cells were observed in the V-MoS<sub>2</sub>@PEG plus 808 nm laser and the V-MoS<sub>2</sub>@PEG groups, indicating efficient photothermal and ·OH-enabled catalytic therapeutic performances, respectively. Measurement of the degree of intracellular oxidative stress and analysis of ·OH production after co-culture with different samples. In Figure 4D, the ·OH was determined using DCFH-DA as a fluorescent probe. Compared with the other three groups, the ·OH level was significantly increased in V-MoS<sub>2</sub>@PEG + NIR group, which indicated that NIR combined with V-MoS<sub>2</sub>@PEG could achieve higher ·OH production. Generally, ·OH production would increase intracellular oxidative stress, promoting cell death. The result of the flow cytometer displayed a similar trend (Figure 4E). The control group or NIR group did not cause cell apoptosis. The V-MoS<sub>2</sub>@PEG and the V-MoS<sub>2</sub>@PEG/NIR groups showed partial apoptosis due to the enzyme-like activity of the V-MoS<sub>2</sub>@PEG and the efficient photothermal of V-MoS<sub>2</sub>@PEG. Due to the V-MoS<sub>2</sub>@PEG has better photothermal properties and ·OH-producing enzyme-like activity, under 808 nm laser irradiation, the vibration between the internal lattices of V-MoS<sub>2</sub>@PEG was intensified, and the V ions and Mo ions became more active, which enhanced the intracellular redox reaction, increased the ·OH-producing efficiency, at the same time, laser irradiation also results in cell hyperthermia, which promotes the process of apoptosis. Figure 4F showed that the apoptotic ratio in the V-MoS<sub>2</sub>@PEG + NIR group reached 75.10% (sum of Q2 + Q3), which was significantly higher than those of the control group (8.74%), NIR group (8.20%), and V-MoS<sub>2</sub>@PEG group (58.61%). As expected, the 4T1 cells treated with V-MoS<sub>2</sub>@PEG + NIR showed the most apoptosis, providing strong evidence that photothermal-induced pyroelectric catalysis and intrinsic nanozymes catalysis co-enhanced ·OH generation, ultimately leading to apoptosis of a significant number of tumor cells. These results show the high synergistic therapeutic efficacy of V-MoS<sub>2</sub>@PEG enabled photothermal-enhanced tumor nanocatalytic therapy, in which huge amounts of highly toxic ·OH and local hyperthermia could be produced to induce apoptosis in the 4T1 cells.

### 3.5 *In vivo* anticancer effect of V-MoS<sub>2</sub>@PEG

We further studied the *in vivo* tumor suppressive efficiency of V-MoS<sub>2</sub>@PEG in 4T1 tumor-bearing mice. The BALB/c mice were randomly allocated into four groups and injected with intravenous injections ( $n = 4$ ): 1. Control; 2. NIR (808 nm, 0.6 W cm<sup>-2</sup>, 10 min); 3. V-MoS<sub>2</sub>@PEG (10 mg kg<sup>-1</sup>); 4. V-MoS<sub>2</sub>@PEG (10 mg kg<sup>-1</sup>) + NIR (10 min) at 0, 3, 6, and 9 d. On day 14, 808 nm laser irradiation operations were executed (Figure 5A). Subsequently, we investigated its suppressed effect in tumor-bearing mice. After treatment completion, the subcutaneous tumors were collected and weighed. Every 2 days, the weights and subcutaneous tumor volumes of the mice were measured (Figures 5B, C), and during the entire treatment process, the changes in mice weight in each group were similar. The mice exhibited negligible weight loss throughout the entire treatment, proving the limited adverse effects of the treatments (Figure 5B). The tumor growth curves

(Figure 5C) showed that the relative tumor volumes of the NIR group were comparable with those of the control group, suggesting that pure NIR irradiation could slightly inhibit tumor growth. The V-MoS<sub>2</sub>@PEG group inhibited tumor growth, confirming that its enzyme activity could kill the tumors, but the effect was limited. The V-MoS<sub>2</sub>@PEG + NIR group exhibited the highest tumor inhibitory effect, and the tumor was almost completely inhibited, owing to the NIR-mediated enzymatic and pyroelectric catalysis. Tumor weight changes were quantified for each group, as shown in Figure 5D, where it can be seen that the most significant changes were seen in the V-MoS<sub>2</sub>@PEG + NIR group. At the end of the treatment, H&E staining images of normal organs after treatment had no apparent tissue damage (Figure 5E), suggesting that V-MoS<sub>2</sub>@PEG possessed superior *in vivo* biocompatibility. H&E staining and Ki67 staining of tumor sections from each group were conducted to demonstrate the excellent tumor suppression effects, indicating that the tumor tissues in the V-MoS<sub>2</sub>@PEG group were severely damaged, while the tissues in the control group and NIR groups exhibited no significant changes (Figure 5F). Similarly, the damage was most severe after the V-MoS<sub>2</sub>@PEG + NIR treatment, and the ALT, AST, Cr, and Urea were used to assess the liver and kidney functions. As shown in Figures 5G–J, no significant damage was observed in the major organs during treatment. These results confirm that V-MoS<sub>2</sub>@PEG promotes apoptosis *in vivo* and can be applied as an innovative nanoplatfrom for cancer therapy.

## 4 Conclusion

In summary, we developed a photothermal therapy/enzyme-catalyzed anti-tumor platform (V-MoS<sub>2</sub>@PEG NFs), which was synthesized using a hydrothermal reaction. The *in vitro* and *in vivo* experiments showed that the Fenton-like reaction based on the redox of Mo and V ions in the TME could achieve the conversion of H<sub>2</sub>O<sub>2</sub> into ·OH while effectively consuming GSH for efficient nanocatalytic tumor therapy in the NIR window (808 nm laser irradiation), and the transfer of electrons during the redox process could also achieve the continuous supply of enzyme-like activity. This was achieved by coating V-MoS<sub>2</sub> NFs with PEG into the V-MoS<sub>2</sub>@PEG nanocomposites. The charge attraction between PEG and V-MoS<sub>2</sub> has led to a significant increase in the V-MoS<sub>2</sub>@PEG stability, improving the material's biocompatibility. The V-MoS<sub>2</sub>@PEG nanozymes acted as a highly efficient Fenton-like agent to generate highly toxic ·OH in specific acidic tumor microenvironments. In addition, the V-MoS<sub>2</sub>@PEG nanozymes exhibited GSH-consumption capability, which impaired the antioxidant defenses of tumor cells and made the cells more sensitive to ROS, thereby further improving the ·OH-mediated tumor nanocatalytic therapy. Most importantly, V-MoS<sub>2</sub>@PEG-enabled photothermal hyperthermia in the NIR-II region significantly enhanced the ability to produce toxic ·OH and the depletion of GSH. As a result, the V-MoS<sub>2</sub>@PEG exerts both enzyme-like activity and photothermal therapy, resulting in enhanced membrane permeability of tumor cells, which improves the chances of nanomedicine deposition and produces an excellent therapeutic effect.

## Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

## Ethics statement

The animal studies were approved by the Ethics Committee of Guangxi Medical University Cancer Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the owners for the participation of their animals in this study.

## Author contributions

HW: Conceptualization, Data curation, Formal Analysis, Investigation, Software, Visualization, Writing—original draft, Writing—review and editing. PX: Data curation, Writing—original draft. MK: Resources, Writing—original draft. SF: Data curation, Writing—original draft. KH: Software, Writing—original draft. SN: Funding acquisition, Resources, Writing—original draft. GJ: Supervision, Writing—review and editing. LZ: Funding acquisition, Supervision, Writing—review and editing. CW: Funding acquisition, Project administration, Supervision, Writing—original draft, Writing—review and editing.

## References

- Albadari, N., Deng, S., and Li, W. (2019). The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. *Expert Opin. Drug Discov.* 14 (7), 667–682. doi:10.1080/17460441.2019.1613370
- An, D., Fu, J., Zhang, B., Xie, N., Nie, G., Ågren, H., et al. (2021). NIR-II responsive inorganic 2D nanomaterials for cancer photothermal therapy: recent advances and future challenges. *Adv. Funct. Mat.* 31 (32), 2101625. doi:10.1002/adfm.202101625
- An, P., Gao, Z., Sun, K., Gu, D., Wu, H., You, C., et al. (2019). Photothermal-enhanced inactivation of glutathione peroxidase for ferroptosis sensitized by an autophagy promoter. *ACS Appl. Mater. Interf.* 11 (46), 42988–42997. doi:10.1021/acsami.9b16124
- Asgharzadeh, M. R., Barar, J., Pourseif, M. M., Eskandani, M., Jafari Niya, M., Mashayekhi, M. R., et al. (2017). Molecular machineries of pH dysregulation in tumor microenvironment: potential targets for cancer therapy. *Bioimpacts* 7 (2), 115–133. doi:10.15171/bi.2017.15
- Cao, Y., Wu, T., Zhang, K., Meng, X., Dai, W., Wang, D., et al. (2019). Engineered exosome-mediated near-infrared-II region V<sub>2</sub>C quantum dot delivery for nucleus-target low-temperature photothermal therapy. *ACS Nano*. 13 (2), 1499–1510. doi:10.1021/acsnano.8b07224
- Cui, G., Chen, S., Jiang, B., Zhang, Y., Qiu, N., Satoh, T., et al. (2013). Synthesis and characterization of novel thermoresponsive fluorescence complexes based on copolymers with rare earth ions. *Opt. Mater* 35 (12), 2250–2256. doi:10.1016/j.optmat.2013.06.010
- Cui, G., Zhao, D., Lv, P., Gao, Z., Chen, S., Qiu, N., et al. (2017). Synthesis and characterization of Eu (III)-based coordination complexes of modified D-glucosamine and poly (N-isopropylacrylamide). *Opt. Mat.* 72, 115–121. doi:10.1016/j.optmat.2017.05.051
- Dong, S., Dong, Y., Jia, T., Liu, S., Liu, J., Yang, D., et al. (2020). GSH-depleted nanozymes with hyperthermia-enhanced dual enzyme-mimic activities for tumor nanocatalytic therapy. *Adv. Mat.* 32 (42), e2002439. doi:10.1002/adma.202002439
- Dong, Y., Dong, S., Liu, B., Yu, C., Liu, J., Yang, D., et al. (2021). 2D piezoelectric Bi<sub>2</sub>MoO<sub>6</sub> nanoribbons for GSH-enhanced sonodynamic therapy. *Adv. Mat.* 33 (51), e2106838. doi:10.1002/adma.202106838
- Fan, L., Xu, X., Zhu, C., Han, J., Gao, L., Xi, J., et al. (2018). Tumor catalytic-photothermal therapy with yolk-shell Gold@Carbon nanozymes. *ACS Appl. Mater. Interf.* 10 (5), 4502–4511. doi:10.1021/acsami.7b17916
- Feng, Z., Chen, G., Zhong, M., Lin, L., Mai, Z., Tang, Y., et al. (2023). An acid-responsive MOF nanomedicine for augmented anti-tumor immunotherapy via a metal ion interference-mediated pyroptotic pathway. *Biomaterials* 302, 122333. doi:10.1016/j.biomaterials.2023.122333
- Ferreira, C. A., Ni, D., Rosenkrans, Z. T., and Cai, W. (2018). Scavenging of reactive oxygen and nitrogen species with nanomaterials. *Nano Res.* 11 (10), 4955–4984. doi:10.1007/s12274-018-2092-y
- Infantino, V., Santarsiero, A., Convertini, P., Todisco, S., and Iacobazzi, V. (2021). Cancer cell metabolism in hypoxia: role of HIF-1 as key regulator and therapeutic target. *Int. J. Mol. Sci.* 22 (11), 5703. doi:10.3390/ijms22115703
- Kobayashi, H., and Choyke, P. L. (2019). Near-infrared photoimmunotherapy of cancer. *Acc. Chem. Res.* 52 (8), 2332–2339. doi:10.1021/acs.accounts.9b00273
- Li, J., Xie, C., Huang, J., Jiang, Y., Miao, Q., and Pu, K. (2018). Semiconducting polymer nanoenzymes with photothermic activity for enhanced cancer therapy. *Angew. Chem. Inter Ed.* 57 (15), 3995–3998. doi:10.1002/anie.201800511
- Li, X., Gao, Y., Li, H., Majoral, J., Shi, X., and Pich, A. (2023). Smart and bioinspired systems for overcoming biological barriers and enhancing disease theranostics. *Prog. Mater. Sci.* 140, 101170. doi:10.1016/j.pmatsci.2023.101170
- Li, X., Sun, H., Li, H., Hu, C., Luo, Y., Shi, X., et al. (2021). Multi-responsive biodegradable cationic nanogels for highly efficient treatment of tumors. *Adv. Funct. Mat.* 31 (26), 2100227. doi:10.1002/adfm.202100227
- Ma, W., Sun, R., Tang, L., Li, Z., Lin, L., Mai, Z., et al. (2023). Bioactivable STING nanoagonists to synergize NIR-II mild photothermal therapy primed robust and long-term anticancer immunity. *Adv. Mat.* 35 (48), e2303149. doi:10.1002/adma.202303149
- Ma, Y., Zhang, Y., Li, X., Zhao, Y., Li, M., Jiang, W., et al. (2019). Near-infrared II phototherapy induces deep tissue immunogenic cell death and potentiates cancer immunotherapy. *ACS Nano*. 13 (10), 11967–11980. doi:10.1021/acsnano.9b06040

## Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by the National Natural Science Foundation (Grant No. 82260580), the Key R&D Program of Scientific Research and Technology Development Project of Guangxi (Grant No. 2022AB11046), the Key R&D Program of Scientific Research and Technology Development Project of Nanning, Guangxi (Grant No. ZC20213009), the Key R&D Program of Scientific Research and Technical Development Project of Qingxiu District, Nanning, Guangxi (Grant No. 2021015), the Youth Science Foundation of Guangxi Medical University (No. GXMUYSF 202318) and Guangxi Medical and health key discipline construction project.

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.



- Ma, Z., Xiang, X., Li, S., Xie, P., Gong, Q., Goh, B. C., et al. (2022). Targeting hypoxia-inducible factor-1, for cancer treatment: recent advances in developing small-molecule inhibitors from natural compounds. *Semin. Cancer Biol.* 80, 379–390. doi:10.1016/j.semcancer.2020.09.011
- Masoud, G. N., and Li, W. (2015). HIF-1 $\alpha$  pathway: role, regulation and intervention for cancer therapy. *Acta Pharm. Sin. B.* 5 (5), 378–389. doi:10.1016/j.apsb.2015.05.007
- Mishra, P., Lee, J., Kumar, D., Louro, R. O., Costa, N., Pathania, D., et al. (2021). Engineered nanoenzymes with multifunctional properties for next-generation biological and environmental applications. *Adv. Funct. Mat.* 32 (8), 2108650. doi:10.1002/adfm.202108650
- Murugan, C., Sharma, V., Murugan, R. K., Malaimegu, G., and Sundaramurthy, A. (2019). Two-dimensional cancer theranostic nanomaterials: synthesis, surface functionalization and applications in photothermal therapy. *J. Control Rel.* 299, 1–20. doi:10.1016/j.jconrel.2019.02.015
- Sahu, P. K., Jayalakshmi, K., Tilgam, J., Gupta, A., Nagaraju, Y., Kumar, A., et al. (2022). ROS generated from biotic stress: effects on plants and alleviation by endophytic microbes. *Front. Plant Sci.* 13, 1042936. doi:10.3389/fpls.2022.1042936
- Sawant, D., and Lilly, B. (2020). MicroRNA-145 targets in cancer and the cardiovascular system: evidence for common signaling pathways. *Vasc. Biol.* 2 (1), R115–R128. doi:10.1530/VB-20-0012
- Sethulekshmi, A. S., Saritha, A., Joseph, K., Aprem, A. S., and Sisupal, S. B. (2022). MoS<sub>2</sub> based nanomaterials: advanced antibacterial agents for future. *J. Control Rel.* 348, 158–185. doi:10.1016/j.jconrel.2022.05.047
- Sindhu, R. K., Najda, A., Kaur, P., Shah, M., Singh, H., Kaur, P., et al. (2021). Potentiality of nanoenzymes for cancer treatment and other diseases: current status and future challenges. *Materials* 14 (20), 5965. doi:10.3390/ma14205965
- Wang, J., Sui, L., Huang, J., Miao, L., Nie, Y., Wang, K., et al. (2021). MoS<sub>2</sub>-based nanocomposites for cancer diagnosis and therapy. *Bioact. Mat.* 6 (11), 4209–4242. doi:10.1016/j.bioactmat.2021.04.021
- Wang, Q., Dai, Y., Xu, J., Cai, J., Niu, X., Zhang, L., et al. (2019). All-in-one phototheranostics: single laser triggers NIR-II fluorescence/photoacoustic imaging guided photothermal/photodynamic/chemo combination therapy. *Adv. Funct. Mater.* 29 (31), 1901480. doi:10.1002/adfm.201901480
- Willems, P. H., Rossignol, R., Dieteren, C. E., Murphy, M. P., and Koopman, W. J. (2015). Redox homeostasis and mitochondrial dynamics. *Cell. Metab.* 22 (2), 207–218. doi:10.1016/j.cmet.2015.06.006
- Wu, F., Tian, M., Sun, Y., Wu, C., and Liu, X. (2022). Efficacy, chemical composition, and pharmacological effects of herbal drugs derived from *Fritillaria cirrhosa* D. Don and *Fritillaria thunbergii* Miq. *Front. Pharmacol.* 13, 985935. doi:10.3389/fphar.2022.985935
- Yadav, V., Roy, S., Singh, P., Khan, Z., and Jaiswal, A. (2019). 2D MoS<sub>2</sub>-based nanomaterials for therapeutic, bioimaging, and biosensing applications. *Small* 15 (1), e1803706. doi:10.1002/smll.201803706
- Yang, H., Villani, R. M., Wang, H., Simpson, M. J., Roberts, M. S., Tang, M., et al. (2018). The role of cellular reactive oxygen species in cancer chemotherapy. *J. Exp. Clin. Cancer Res.* 37 (1), 266. doi:10.1186/s13046-018-0909-x
- Yang, S., and Lian, G. (2020). ROS and diseases: role in metabolism and energy supply. *Mol. Cell. Biochem.* 467 (1–2), 1–12. doi:10.1007/s11010-019-03667-9
- Yang, Y., Fan, X., Li, L., Yang, Y., Nuernisha, A., Xue, D., et al. (2020). Semiconducting polymer nanoparticles as theranostic system for near-infrared-II fluorescence imaging and photothermal therapy under safe laser fluence. *ACS Nano* 14 (2), 2509–2521. doi:10.1021/acsnano.0c00043
- Zhang, B., Pan, C., Feng, C., Yan, C., Yu, Y., Chen, Z., et al. (2022). Role of mitochondrial reactive oxygen species in homeostasis regulation. *Redox Rep.* 27 (1), 45–52. doi:10.1080/13510002.2022.2046423
- Zhang, C., Wang, X., Du, J., Gu, Z., and Zhao, Y. (2020a). Reactive oxygen species-regulating strategies based on nanomaterials for disease treatment. *Adv. Sci.* 8 (3), 2002797. doi:10.1002/advs.202002797
- Zhang, Q., Guo, Q., Chen, Q., Zhao, X., Pennycook, S. J., and Chen, H. (2020b). Highly efficient 2D NIR-II photothermal agent with fenton catalytic activity for cancer synergistic photothermal-chemodynamic therapy. *Adv. Sci.* 7 (7), 1902576. doi:10.1002/advs.201902576
- Zhang, X.-R., Chen, Y.-H., Guo, Q.-S., Wang, W.-M., Liu, L., Fan, J., et al. (2017). Short-term UV-B radiation effects on morphology, physiological traits and accumulation of bioactive compounds in *Prunella vulgaris* L. *J. Plant Interact.* 12 (1), 348–354. doi:10.1080/17429145.2017.1365179
- Zhou, H., Zeng, X., Li, A., Zhou, W., Tang, L., Hu, W., et al. (2020). Upconversion NIR-II fluorophores for mitochondria-targeted cancer imaging and photothermal therapy. *Nat. Commun.* 11 (1), 6183. doi:10.1038/s41467-020-19945-w